Published on
06:59 GMT
FDA Pushes for New Buprenorphine Labeling
The US Food and Drug Administration (FDA) is urging manufacturers to revise labeling of transmucosal buprenorphine products to ease access to higher doses needed due to the rise of high-potency opioids like fentanyl. The agency published its proposal in …
Source:
Medscape
-
Neutral
